20233.00 +25.35 (0.13%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
20175.9
Today’s High
20306.9
52 Week Low
15426.74
52 Week High
20895.0
20200.05 +3.85 (0.02%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
20172.1
Today’s High
20317.35
52 Week Low
15415.83
52 Week High
20900.8
Key Metrics
- Market Cap (In Cr) 42624.83
- Beta 0.22
- Div. Yield (%) 0.72
- P/B 15.12
- TTM P/E 46.12
- Peg Ratio 9.37
- Sector P/E 27.15
- D/E 0.05
- Open Price 20265.1
- Prev Close 20207.65
Analysis
Price Analysis
-
1 Week-0.35%
-
3 Months10.16%
-
6 Month14.11%
-
YTD3.6%
-
1 Year6.26%
Risk Meter
- 22% Low risk
- 22% Moderate risk
- 22% Balanced Risk
- 22% High risk
- 22% Extreme risk
Recos
9 Analysts
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- Strong Sell
- 2
- Sell
- 0
- Hold
- 2
- Buy
- 1
- Strong Buy
- 4
Abbott India News
Rajesh Palviya of Axis Securities recommends 3 stocks to buy today — 30 Sept
3 min read . 30 Sep 2022
Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2022
- Total Revenue
- 4919.27
- Selling/ General/ Admin Expenses Total
- 1086.89
- Depreciation/ Amortization
- 66.1
- Other Operating Expenses Total
- 57.26
- Total Operating Expense
- 3892.34
- Operating Income
- 1026.93
- Net Income Before Taxes
- 1079.73
- Net Income
- 798.7
- Diluted Normalized EPS
- 375.87
- Period
- 2022
- Total Assets
- 4224.12
- Total Liabilities
- 1404.33
- Total Equity
- 2819.79
- Tangible Book Valueper Share Common Eq
- 1322.94
- Period
- 2022
- Cashfrom Operating Activities
- 947.66
- Cashfrom Investing Activities
- -395.84
- Cashfrom Financing Activities
- -637.38
- Net Changein Cash
- -85.56
- Period
- 2021
- Total Revenue
- 4310.02
- Selling/ General/ Admin Expenses Total
- 918.82
- Depreciation/ Amortization
- 58.13
- Other Operating Expenses Total
- 53.77
- Total Operating Expense
- 3441.5
- Operating Income
- 868.52
- Net Income Before Taxes
- 925.95
- Net Income
- 690.69
- Diluted Normalized EPS
- 325.12
- Period
- 2021
- Total Assets
- 3840.45
- Total Liabilities
- 1238.29
- Total Equity
- 2602.16
- Tangible Book Valueper Share Common Eq
- 1224.04
- Period
- 2021
- Cashfrom Operating Activities
- 726.74
- Cashfrom Investing Activities
- -71.82
- Cashfrom Financing Activities
- -581.79
- Net Changein Cash
- 73.13
- Period
- 2020
- Total Revenue
- 4093.14
- Selling/ General/ Admin Expenses Total
- 929.42
- Depreciation/ Amortization
- 59.61
- Other Operating Expenses Total
- 59.3
- Total Operating Expense
- 3386.48
- Operating Income
- 706.66
- Net Income Before Taxes
- 802.69
- Net Income
- 592.93
- Diluted Normalized EPS
- 279.22
- Period
- 2020
- Total Assets
- 3546.85
- Total Liabilities
- 1115.14
- Total Equity
- 2431.71
- Tangible Book Valueper Share Common Eq
- 1143.95
- Period
- 2020
- Cashfrom Operating Activities
- 626.11
- Cashfrom Investing Activities
- -401.19
- Cashfrom Financing Activities
- -216.79
- Net Changein Cash
- 8.13
- Period
- 2019
- Total Revenue
- 3678.6
- Selling/ General/ Admin Expenses Total
- 914.55
- Depreciation/ Amortization
- 16.92
- Other Operating Expenses Total
- 47
- Total Operating Expense
- 3085.21
- Operating Income
- 593.4
- Net Income Before Taxes
- 698.85
- Net Income
- 450.33
- Diluted Normalized EPS
- 209
- Period
- 2019
- Total Assets
- 2940.91
- Total Liabilities
- 932.33
- Total Equity
- 2008.59
- Tangible Book Valueper Share Common Eq
- 944.38
- Period
- 2019
- Cashfrom Operating Activities
- 499.13
- Cashfrom Investing Activities
- -257
- Cashfrom Financing Activities
- -142.8
- Net Changein Cash
- 99.33
- Period
- 2018
- Total Revenue
- 3307.12
- Selling/ General/ Admin Expenses Total
- 802.68
- Depreciation/ Amortization
- 16.19
- Other Operating Expenses Total
- 46.66
- Total Operating Expense
- 2793.21
- Operating Income
- 513.91
- Net Income Before Taxes
- 621.48
- Net Income
- 401.22
- Diluted Normalized EPS
- 175.14
- Period
- 2018
- Total Assets
- 2416.19
- Total Liabilities
- 723.43
- Total Equity
- 1692.76
- Tangible Book Valueper Share Common Eq
- 795.3
- Period
- 2018
- Cashfrom Operating Activities
- 152.7
- Cashfrom Investing Activities
- -214.84
- Cashfrom Financing Activities
- -102.43
- Net Changein Cash
- -164.56
- Period
- 2017
- Total Revenue
- 2938.69
- Selling/ General/ Admin Expenses Total
- 717.7
- Depreciation/ Amortization
- 16.43
- Other Operating Expenses Total
- 56.1
- Total Operating Expense
- 2552.78
- Operating Income
- 385.91
- Net Income Before Taxes
- 436.49
- Net Income
- 276.65
- Diluted Normalized EPS
- 130.25
- Period
- 2017
- Total Assets
- 2065.8
- Total Liabilities
- 678.86
- Total Equity
- 1386.94
- Tangible Book Valueper Share Common Eq
- 651.25
- Period
- 2017
- Cashfrom Operating Activities
- 307.22
- Cashfrom Investing Activities
- -155.41
- Cashfrom Financing Activities
- -89.76
- Net Changein Cash
- 62.04
- Period
- 2022-09-30
- Total Revenue
- 1379.48
- Selling/ General/ Admin Expenses Total
- 149.56
- Depreciation/ Amortization
- 17.47
- Other Operating Expenses Total
- 134.5
- Total Operating Expense
- 1053.65
- Operating Income
- 325.83
- Net Income Before Taxes
- 355.39
- Net Income
- 265.52
- Diluted Normalized EPS
- 124.95
- Period
- 2022-09-30
- Total Assets
- 4100.16
- Total Liabilities
- 1385.67
- Total Equity
- 2714.49
- Tangible Book Valueper Share Common Eq
- 1273.63
- Period
- 2022-09-30
- Cashfrom Operating Activities
- 370.21
- Cashfrom Investing Activities
- 401.49
- Cashfrom Financing Activities
- -611.44
- Net Changein Cash
- 160.26
- Period
- 2022-06-30
- Total Revenue
- 1304.37
- Selling/ General/ Admin Expenses Total
- 152.09
- Depreciation/ Amortization
- 17.35
- Other Operating Expenses Total
- 163.86
- Total Operating Expense
- 1051.32
- Operating Income
- 253.05
- Net Income Before Taxes
- 275.19
- Net Income
- 205.64
- Diluted Normalized EPS
- 96.77
- Period
- 2022-06-30
- Period
- 2022-06-30
- Period
- 2022-03-31
- Total Revenue
- 1255.02
- Selling/ General/ Admin Expenses Total
- 135.48
- Depreciation/ Amortization
- 17.43
- Other Operating Expenses Total
- 149.71
- Total Operating Expense
- 978.63
- Operating Income
- 276.39
- Net Income Before Taxes
- 292.3
- Net Income
- 211.41
- Diluted Normalized EPS
- 99.5
- Period
- 2022-03-31
- Total Assets
- 4224.12
- Total Liabilities
- 1404.33
- Total Equity
- 2819.79
- Tangible Book Valueper Share Common Eq
- 1322.94
- Period
- 2022-03-31
- Cashfrom Operating Activities
- 947.66
- Cashfrom Investing Activities
- -395.84
- Cashfrom Financing Activities
- -637.38
- Net Changein Cash
- -85.56
- Period
- 2021-12-31
- Total Revenue
- 1224.36
- Selling/ General/ Admin Expenses Total
- 141.62
- Depreciation/ Amortization
- 16.74
- Other Operating Expenses Total
- 164.97
- Total Operating Expense
- 972.04
- Operating Income
- 252.32
- Net Income Before Taxes
- 266.65
- Net Income
- 199.2
- Diluted Normalized EPS
- 93.74
- Period
- 2021-12-31
- Period
- 2021-12-31
- Period
- 2021-09-30
- Total Revenue
- 1222.06
- Selling/ General/ Admin Expenses Total
- 156.89
- Depreciation/ Amortization
- 16.2
- Other Operating Expenses Total
- 152.38
- Total Operating Expense
- 978.57
- Operating Income
- 243.49
- Net Income Before Taxes
- 257.19
- Net Income
- 192.33
- Diluted Normalized EPS
- 90.51
- Period
- 2021-09-30
- Total Assets
- 3719.99
- Total Liabilities
- 1311.09
- Total Equity
- 2408.9
- Tangible Book Valueper Share Common Eq
- 1130.9
- Period
- 2021-09-30
- Cashfrom Operating Activities
- 466.79
- Cashfrom Investing Activities
- -14.8
- Cashfrom Financing Activities
- -610.63
- Net Changein Cash
- -158.64
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Technical
Moving Average
SMA
- 5 Day20242.55
- 10 Day20147.76
- 20 Day19824.99
- 50 Day19119.4
- 100 Day19085.48
- 300 Day18225.24
Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Dr Reddys Laboratories
- 4355.05
- -18.95
- -0.43
- 4930
- 3655
- 74381.13
- Torrent Pharmaceuticals
- 1626
- 7.85
- 0.49
- 1722.7
- 1235.88
- 54824.78
- Abbott India
- 20233
- 25.35
- 0.13
- 20895
- 15426.74
- 42624.83
- Zydus Lifesciences
- 405.8
- -4.3
- -1.05
- 487
- 319.4
- 41849.58
- Alkem Laboratories
- 3078.15
- -18.3
- -0.59
- 3784
- 2835
- 37302.49
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Dr Reddys Laboratories
- 26.99
- 3.87
- 12.1
- 10.32
- Torrent Pharmaceuticals
- 50.55
- 9.21
- 16.36
- 10.81
- Abbott India
- 53.37
- 15.12
- 27.07
- 14.45
- Zydus Lifesciences
- 19.68
- 2.49
- 17
- 13.51
- Alkem Laboratories
- 22.68
- 4.32
- 18.92
- 14.07
Shareholding
- Category
- Percentage
- No. of shares
- Promoter & Promoter Group Shareholding
- 74.99%
- 15,934,048
- ABBOTT CAPITAL INDIA LIMITED
- 50.44%
- 10,719,097
- ABBOTT HEALTHCARE PRODUCTS LIMITED
- 17.62%
- 3,744,951
- BRITISH COLLOIDS LIMITED
- 6.92%
- 1,470,000
- Public Shareholding
- 25.01%
- 5,315,254
- Others
- 14.38%
- 3,056,264
- CANARA ROBECO MUTUAL FUND A/C CANARA ROBECO EMERGING EQUITIES
- 1.29%
- 273,904
- Others
- 4.38%
- 930,377
- LIFE INSURANCE CORPORATION OF INDIA
- 1.07%
- 226,689
- Others
- 0.97%
- 207,640
- Others
- 0.73%
- 154,627
- Others
- 0.62%
- 131,522
- Others
- 0.53%
- 113,639
- Others
- 0.47%
- 99,583
- Others
- 0.22%
- 46,642
- Others
- 0.2%
- 43,299
- Others
- 0.12%
- 25,421
- Others
- 0.02%
- 4,819
- Others
- 0%
- 657
- Others
- 0%
- 126
- Others
- 0%
- 45
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 14-Nov-22
- Quarterly Results
- 10-Aug-22
- Quarterly Results
- 17-May-22
- Audited Results & Dividend
- 09-Feb-22
- Quarterly Results
- 12-Nov-21
- Quarterly Results
- 06-Aug-21
- Quarterly Results
- 18-May-21
- Audited Results & Final Dividend
- 09-Feb-21
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 10-Aug-22
- 17-May-22
- AGM
- 28-Mar-22
- 23-Feb-22
- POM
- 27-Jul-21
- 18-May-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 17-May-22
- -
- 02-Aug-22
- 145
- 18-May-22
- -
- 02-Aug-22
- 130
- 18-May-21
- -
- 19-Jul-21
- 120
- 19-May-21
- -
- 19-Jul-21
- 155
No recent bonus announcements.
No recent splits available.
No recent rights issue declared.
Company Profile
ABOUT Abbott India
- Industry Biotechnology & Drugs
- ISIN INE358A01014
- BSE Code 500488
- NSE Code ABBOTINDIA
Abbott India Limited is an India-based company that is engaged in pharmaceuticals business. The Company has a portfolio of offerings in diagnostics, medical devices, nutrition products and branded generic medicines. It provides products and solutions across various therapeutic areas, such as women's health, gastroenterology, central nervous system, metabolics, multi-specialty, vaccines and consumer health, among others. Its products include Colospa (irritable bowel disease), Ganaton (gastrointestinal motility), Librax (irritable bowel disease), Zolfresh (insomnia), Thyronorm (hypothyroidism), Duphaston (miscarriage and IVF), Duphalac (constipation), Digene (antacid), Prothiaden (pain and depression), Influvac (prevention of influenza), Creon (pancreatic insufficiency), Cremalax (constipation), Pankreoflat (indigestion) and Duvadilan (preterm labor), among others. It offers various products under brands, such as Similac, PediaSure, Pedialyte, EleCare, Ensure and Glucerna, among others.
MANAGEMENT
- Sridhar Kadangode Director - Finance
- Krupa Anandpara Compliance Officer, Associate Director - Secretarial & Company Secretary
- Vivek Kamath Managing Director, Additional Director
- Kunal Chowdhury Commercial Director - GI Business
- Prateek Gupta Director - Commercial Excellence
- Rajan Kalantre Director - Business Human Resources
- Jejoe Karankumar Director - Medical Affairs
- Shantaprasad Nagarmath Commercial Director – Gennext, Vaccines and Consumer Health
- T. Prasad Commercial Director - Specialty Care
- Sandeep Reddy Associate Director - Women’s Health
Company Summary
ABBOTT INDIA SUMMARY
Abbott India is trading 0.13% upper at Rs 20233.00 as compared to its last closing price. Abbott India has been trading in the price range of 20306.9 & 20175.9. Abbott India has given 3.6% in this year & -0.35% in the last 5 days.
Abbott India has TTM P/E ratio 46.12 as compared to the sector P/E of 27.15. There are 9 analysts who have initiated coverage on Abbott India. There are 4 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 0 analysts have given the stock a sell rating.
The company posted a net profit of 265.52 Crores in its last quarter.
Listed peers of Abbott India include Dr Reddys Laboratories (-0.43%), Torrent Pharmaceuticals (0.49%), Abbott India (0.13%) etc.
FAQs about Abbott India
Abbott India is trading at 20233.00 as on 7 Dec, 2022 3:29:07 PM. This is 0.13% upper as compared to its previous closing price of 20207.65
The market capitalization of Abbott India is 42624.83 Cr as on 7 Dec, 2022 3:29:07 PM.
The average broker rating on Abbott India is Buy. The breakup of analyst rating is given below -
- 2 analysts have given a strong sell rating
- 0 analysts have given a sell rating
- 2 analysts have given a hold rating
- 1 analysts have given a buy rating
- 4 analysts have given a strong buy rating
The 52 wk high for Abbott India is 20895.0 whereas the 52 wk low is 15426.74
Abbott India can be analyzed on the following key metrics -
- TTM P/E: 46.12
- Sector P/E: 27.15
- Dividend Yield: 0.72%
- D/E ratio: -
Abbott India reported a net profit of 798.7 Cr in 2022.
